Get the Stockscreener App
144.86
2.67%
-3.98
After Hours:
144.86
Biogen Inc stock is traded at $144.86, with a volume of 1.81M.
It is down -2.67% in the last 24 hours and up +12.36% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$148.84
Open:
$148.08
24h Volume:
1.81M
Relative Volume:
1.29
Market Cap:
$21.24B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
13.85
EPS:
10.46
Net Cash Flow:
$1.85B
1W Performance:
+2.98%
1M Performance:
+12.36%
6M Performance:
+3.33%
1Y Performance:
-26.80%
1-Day Range:
$144.84
$150.28
1-Week Range:
$137.20
$150.28
52-Week Range:
$110.03
$204.18
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
144.86 | 20.91B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 27,353 Shares of Biogen Inc. $BIIB - MarketBeat
Jacobs Levy Equity Management Inc. Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Acquired by Gotham Asset Management LLC - MarketBeat
Adage Capital Partners GP L.L.C. Purchases Shares of 70,767 Biogen Inc. $BIIB - MarketBeat
Alliancebernstein L.P. Acquires 48,331 Shares of Biogen Inc. $BIIB - MarketBeat
Is Biogen Stock Underperforming the Nasdaq? - MSN
Is Biogen Stock Underperforming The Nasdaq? - Barchart.com
Piper Sandler Adjusts Price Target on Biogen to $118 From $115, Maintains Neutral Rating - MarketScreener
Fred Alger Management LLC Takes $1.66 Million Position in Biogen Inc. $BIIB - MarketBeat
Nissay Asset Management Corp Japan ADV Raises Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
How Josh is Modernizing Manufacturing - Biogen
Teza Capital Management LLC Invests $349,000 in Biogen Inc. $BIIB - MarketBeat
Royal Bank of Canada Purchases 85,127 Shares of Biogen Inc. $BIIB - MarketBeat
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - Investing News Network
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Vident Advisory LLC Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Purchased by Amundi - MarketBeat
Cinctive Capital Management LP Acquires Shares of 7,894 Biogen Inc. $BIIB - MarketBeat
Interview with Priya Singhal: Building a strong pipeline of innovative medicines - Biogen
Focus Partners Advisor Solutions LLC Takes Position in Biogen Inc. $BIIB - MarketBeat
Cutaneous lupus erythematosus Market: Epidemiology, - openPR.com
Cutter Capital Management LP Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Needham & Company LLC Reaffirms "Hold" Rating for Biogen (NASDAQ:BIIB) - MarketBeat
AQR Capital Management LLC Acquires 829,150 Shares of Biogen Inc. $BIIB - MarketBeat
Raymond James Financial Inc. Sells 100,005 Shares of Biogen Inc. $BIIB - MarketBeat
Can Biogen Inc. lead its sector in growth2025 Price Momentum & Daily Oversold Bounce Ideas - Lancaster City Council
The Manufacturers Life Insurance Company Lowers Position in Biogen Inc. $BIIB - MarketBeat
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline - BioSpace
X-linked retinitis pigmentosa Pipeline Analysis & Clinical - openPR.com
Biogen at Morgan Stanley Conference: Strategic Shift in Focus - Investing.com
Biogen (BIIB) Valuation in Focus After FDA Nod for At-Home Leqembi, Dravet Therapy Progress - simplywall.st
Biogen Inc. Attempts Reversal From Key SupportMarket Movers & Daily Stock Momentum Reports - beatles.ru
Biogen (NASDAQ:BIIB) Stock Price Up 5.1%Still a Buy? - MarketBeat
Banque Transatlantique SA Makes New $428,000 Investment in Biogen Inc. $BIIB - MarketBeat
Priya Singhal Sells 517 Shares of Biogen (NASDAQ:BIIB) Stock - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):